2-苯基-3-硝基吡啶 | 134896-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-苯基-3-硝基吡啶
• 英文名称: 2-phenyl-3-nitropyridine
• 英文别名: 3-Nitro-2-phenylpyridine
• CAS: 134896-35-8
• 化学式: C₁₁H₈N₂O₂
• 分子量: 200.197
• InChiKey: GEALTJGFPPNOJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下应保持干燥和密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Nitro-2-phenylpyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Nitro-2-phenylpyridine
CAS number: 134896-35-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H8N2O2
Molecular weight: 200.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-苯基-3-硝基吡啶 在 palladium hydroxide - carbon 盐酸 、 氢气 作用下， 以 乙醇 为溶剂， 生成 cis-(+/-)-2-phenylpiperidin-3-ylamine
  参考文献：
  名称：

  Tetrazole NK1 receptor antagonists: The identification of an exceptionally potent orally active antiemetic compound

  摘要：

  The medicinal chemistry strategy is described which led to the identification of GR205171, an orally active non-peptide neurokinin-1 receptor antagonist that is the most potent broad-spectrum antiemetic agent reported to date. (C) 1996 Elsevier Science Ltd.

  DOI：

  10.1016/0960-894x(96)00163-1
• 作为产物：
  描述：

  2-氯-3-硝基吡啶 以97的产率得到2-苯基-3-硝基吡啶
  参考文献：
  名称：

  F-18 radiolabeled neurokinin-1 receptor antagonists

  摘要：

  本发明涉及放射性标记的神经激肽-1受体拮抗剂，可用于哺乳动物神经激肽-1受体的标记和诊断成像。

  公开号：

  US06241964B1

文献信息

• Coupling of heteroaryl chlorides with arylboronic acids in the presence of [1,4-bis-(diphenylphosphine)butane]palladium(II) dichloride
  作者：M.B. Mitchell、P.J. Wallbank

  DOI：10.1016/s0040-4039(00)79700-0

  日期：1991.5

  The cross-coupling of arylboronic acids with a variety of π-deficient heteroaryl chlorides has been shown to occur in high yield in the presence of [1,4-bis-(diphenylphosphine)butane]palladium(II) dichloride as catalyst.

  在[1，4-双-（二苯基膦基）丁烷]二氯化钯（II）作为催化剂存在下，芳基硼酸与多种π-缺陷的杂芳基氯化物的交叉偶联显示出高收率。
• NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160176864A1

  公开（公告）日：2016-06-23

  The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及三环化合物，包括本发明化合物的药用可接受组合物以及在治疗各种疾病中使用所述组合物的方法。
• Metal-Free Deoxygenation and Reductive Disilylation of Nitroarenes by Organosilicon Reducing Reagents
  作者：Argha Bhattacharjee、Hiromu Hosoya、Hideaki Ikeda、Kohei Nishi、Hayato Tsurugi、Kazushi Mashima

  DOI：10.1002/chem.201801972

  日期：2018.8.6

  A metal‐free deoxygenation and reductive disilylation of nitroarenes was achieved using N,N′‐bis(trimethylsilyl)‐4,4′‐bipyridinylidene (1) under mild and neutral reaction conditions, and a broad functional group tolerance was possible in this reaction. Mono‐deoxygenation, giving a synthetically valuable N,O‐bis(trimethylsilyl)phenylhydroxylamine (7 a) as a readily available and safe phenylnitrene source

  使用N，N'-双（三甲基甲硅烷基）-4,4'-联吡啶亚烷基（1）在温和和中性的反应条件下实现了硝基芳烃的无金属脱氧和还原二甲硅烷基化反应，并且该反应可能具有广泛的官能团耐受性。单脱氧可得到合成上有价值的N，O-双（三甲基甲硅烷基）苯羟胺（7 a），是一种容易获得且安全的硝基苯来源的苯基亚硝酸，双脱氧可得到N，N-双（三甲基硅烷基）苯胺8。改变1的量很容易控制反应温度以及加入二苯并噻吩（DBTP）。2-芳基硝基苯与1的反应通过N，O-双（三甲基甲硅烷基）苯基羟胺7的热解衍生的原位生成的亚苯基硝基苯胺生成相应的咔唑14，随后将其插入分子内CH。此外，分子内的N-N偶联反应将2,2'-二硝基联苯衍生物还原1，得到相应的苯并[ c ]喹啉。
• Substituted piperidines and methods of use
  申请人：——

  公开号：US20040006067A1

  公开（公告）日：2004-01-08

  Selected substituted piperidine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的替代哌啶化合物对预防和治疗疾病，如肥胖等，具有有效性。该发明涵盖了新颖化合物、类似物、前药和其药用可接受盐，以及用于预防和治疗涉及黑素皮质素受体激活的疾病和其他疾病或病症的药物组合物和方法。该发明还涉及制备此类化合物的方法，以及在此类方法中有用的中间体。
• [EN] SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS AMINÉS À SUBSTITUTION ARYLE ET PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2006012374A1

  公开（公告）日：2006-02-02

  The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

  本发明提供了一类化合物，包括其药用可接受的衍生物，用于治疗血管生成和相关疾病，如癌症。其中R为从7-异喹啉基、2-甲基-3-氧代-2,3-二氢吲哚-6-基、[1,6]-萘啶-3-基、[1,7]-萘啶-2-基、1-氧代-2,3-二氢苯并呋喃-4-基、3-氧代-2,3-二氢苯并呋喃-5-基、二氢苯并二氧杂环基、6-喹唑啉基、2-氨基-6-喹唑啉基、4-甲氨基-6-喹唑啉基、2,4-二氨基-6-喹唑啉基、3-氧代-3,4-二氢-1,4-苯并噁嗪-6-基、2,2-二氟-1,3-苯并二氧杂环-5-基和2,2,3,3-四氟-2,3-二氢-1,4-苯并二氧杂环-6-基中选择的9-或10-成员杂环基，其中每个基可选择地被一个或多个来自卤素、卤代烷基、C1-6烷基、C2-8烯基、C2-8炔基、N-二甲氨基-C1-6-烷基、N-二甲氨基-C1-6-烷氧基、氨基、烷基-羰基氨基、吗啉磺酰基、氨基磺酰基、噁唑基、吡咯基、吗啉基、羧基、氰基和乙酰基的取代基取代；其中式I中的R1从未取代或取代的苯基、5-6成员杂芳基、9-10成员双环杂环基和11-14成员三环杂环基中选择，式II中的R1从特定的双环杂环基中选择。

表征谱图